CIN-107 for High Blood Pressure in Chronic Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you continue taking an ACE inhibitor or angiotensin receptor blocker at the maximum tolerated dose. However, you must be willing to stop taking a mineralocorticoid receptor antagonist or a potassium-sparing diuretic if you are currently using them.
Is CIN-107 safe for humans?
How does the drug CIN-107 differ from other treatments for high blood pressure in chronic kidney disease?
CIN-107 is unique because it is being specifically studied for its effects on high blood pressure in patients with chronic kidney disease, whereas other treatments like cilnidipine, a calcium channel blocker, are known for their reno-protective actions and blood pressure reduction but are not specifically tailored for this condition. Additionally, CIN-107's mechanism of action or specific benefits compared to existing treatments are not detailed in the provided research, making it a novel option under investigation.14678
What is the purpose of this trial?
This trial is testing a new medication called CIN-107 to see if it can help lower blood pressure in patients whose high blood pressure isn't controlled by current treatments and who also have kidney disease. The medication likely works by helping blood flow more easily or reducing body fluid.
Eligibility Criteria
This trial is for adults with uncontrolled high blood pressure and mild-to-severe chronic kidney disease who are already taking the maximum tolerated dose of ACEi or ARB medications. People with type 1 diabetes, recent major heart issues, certain unstable conditions, extreme lab values, a BMI over 50, severe renal artery stenosis, known allergies to CIN-107 or similar drugs, recent immunotherapy for CKD, positive HIV/hepatitis tests or excessive alcohol intake cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Double-Blind Treatment
Participants receive either placebo or CIN-107 (low or high dose) for 26 weeks, with dose titration possible within the first 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CIN-107
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
CinCor Pharma, Inc.
Lead Sponsor
Parexel
Industry Sponsor
Peyton Howell
Parexel
Chief Executive Officer
Master of Healthcare Administration from The Ohio State University, Bachelor of Arts in Health Communications from the University of Illinois
Dr. Austin Smith
Parexel
Chief Medical Officer since 2023
MD from the Royal College of Surgeons in Ireland